The Canadian government has given permission to a startup to ship psychedelic substances to Australia for medicinal use. Optimi Health Corp. is responsible for the distribution of pills containing psilocybin, a compound found in magic mushrooms, and MDMA, as approved by the health department.
Demand is growing not just locally for magic mushrooms Ontario, but internationally as well. Other countries are following Canada’s lead and beginning to authorize the medical use of serotogenic compounds.
You can confidently buy psychedelics online in Canada and tap into your innate potential through trustworthy sources.
[toc]Main Points:
- Vancouver-based startup Optimi Health has received a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in the treatment of chronic depression.
- The treatment plan typically involves three sessions, spread out over five to eight weeks, with each session lasting around eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based startup, aims to use its licensing to broaden the pharmaceutical market for psychedelic substances and gain early market entry.
Seven companies have exported psilocybin, MDMA, or both, but only for the purpose of clinical trials. A representative from the health department in Canada couldn’t confirm whether these exports were for regular patient treatment and chose not to reveal the companies for security reasons.
This accomplishment puts Optimi in a unique group of international suppliers, with the current market focus being more clinical than recreational.
What’s in the Pill?
The company hasn’t disclosed the specific type of mushroom used in the pill, but they do utilize a range of strains including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, for the cultivation, testing, and extraction of its psychedelic mushrooms. This quaint town, home to approximately 3,000 residents, is situated three hours east of Vancouver.
Australia’s Relationship with Psychedelic Mushrooms
Approximately one in five Australians aged between 16 and 85 are expected to experience a mental illness. PTSD (post-traumatic stress disorder) could impact 11% of Australians at some point, and anxiety disorders are common in 17% of the population.
There is a broad spectrum of methods to treat mental health disorders, but not every method is effective for all individuals. Patients who don’t find success with certain treatments may struggle to find an alternative that works for them, thus increasing their vulnerability.
Understanding the Process
Australia has been at the forefront of using psilocybin, allowing licensed psychiatrists to treat PTSD and depression that is resistant to traditional treatments with this controlled substance.
In an unexpected move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic use. The TGA asserted that these substances are safe when used in a medically supervised environment for patients with severe mental conditions.
This shift has been transformative for many mental health professionals and researchers. The use of these substances will be rigorously monitored; it’s not as simple as taking a pill and leaving.
The treatment protocol typically includes three sessions spread over five to eight weeks. Each session lasts approximately eight hours, with the therapist staying with the patient throughout.
Canada’s Role in Psilocybin Research
Canada has become a significant center for psilocybin research, greatly advancing our understanding of this compound. Health Canada, in collaboration with several institutions, is leading the investigation into the therapeutic potential of psilocybin in treating various mental health disorders.
Research institutions are no longer obligated to classify these substances as illegal or rely on unauthorized dispensaries or mushroom stores. The government now permits certain institutions to grow mushrooms for research purposes.
Having newfound access to substances previously deemed harmful enables researchers to deepen their understanding of their potential benefits for many individuals.
A Recurring Developments
The potential of this domain to address mental health problems and substance misuse, including alcoholism, was first acknowledged in the 1950s. The pioneers of this early research included English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer, who conducted their studies at the Weyburn Mental Hospital in Saskatchewan. Notably, this institution advanced significantly under the leadership of then-Premier Tommy Douglas, who allowed the medical community substantial freedom to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer embarked on studies involving LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their research took unexpected paths, with the pair advocating for medical staff, including doctors, nurses, and support staff, to experiment with these drugs.
Canadian Health Research Institutes
The Canadian Institutes of Health Research, through its Institute of Neurosciences, Mental Health and Addiction, is funding three clinical trials to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Category | Study Objective | Research Institution | Principal Investigator | Project Funding |
| A randomized controlled trial | Psychological distress in end-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Understanding the mechanisms underpinning psilocybin therapy for alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
These research funds will enhance our understanding of controlled substances’ potential benefits. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Government of Canada, has made this funding possible.
Further Psychedelic Research
Psychiatrists in Vancouver have begun a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment involves three MDMA sessions, each lasting eight hours, spaced a month apart, in addition to nine 90-minute sessions without the drug. Researchers view this trial as historically significant as it is the first clinical investigation of an illicit substance.
It has been over forty years since a psychedelic substance was discovered.
An Introduction to Psilocybin
Psilocybin, a naturally occurring psychedelic compound, is present in certain types of mushrooms. Upon ingestion, it is metabolized to psilocin which then stimulates the serotonin 5-HT2a receptors in the cortical pyramidal cells of the brain, the main processing sites.
Local authorities are examining its potential use in aiding with conditions such as depression, anxiety, addiction, and distress related to end-of-life, by promoting introspection and spiritual enlightenment.
How is it Potentially Beneficial for Conditions Like Depression, PTSD, and Beyond?
The active ingredient affects several brain areas, making it potentially beneficial for a range of mental conditions. A number of patients in Canada and Australia have been treated using this therapy and the results are promising, with minor side effects such as transient anxiety or elevated blood pressure.
The Impact on Neurobiology
- Activation of Serotonin Receptors: The substance functions as a partial agonist at serotonin receptors, particularly the 5-HT2A subtype, which plays a vital role in emotional processing and mood regulation.
- Modulation of the Default Mode Network (DMN): The activity in the DMN is reduced, promoting introspection, mitigating rigid thought patterns, and enhancing emotional flexibility.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the substance are due to its influence on the prefrontal and limbic areas of the brain, including the amygdala. In individuals with depression, there is often a reduced response to emotional stimuli. The substance increases the response to positive emotional stimuli in the right amygdala and decreases or normalizes the response to negative or neutral emotional stimuli.
Impacts on Psychology and Emotions:
- Generation of Positive Mood States: It induces feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience could allow individuals to confront and process deep-seated emotions, traumatic memories, or existential concerns in a safe and supportive setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College London suggests that it can contribute to ongoing positive changes, such as improved wellness, increased life contentment, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Retailers?
Interested in how the substance can impact your mental health? You can explore magic mushroom stores to locate a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, triggers creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and ameliorates overall life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Provokes clarity, creativity, and concentration. Contains a strong mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy advantages |
Psilocybin’s Worldwide Recognition
Canada isn’t the sole country advocating the employment of magic mushrooms for mental health conditions. Countries like Australia are also accepting the use of these psychedelics to treat issues such as depression and PTSD. They are procuring top-quality psychedelic capsules from trustworthy countries. With proper guidance, patients can significantly elevate their life quality. Mushrooms Online Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Both psilocybin and MDMA carry therapeutic potential by enhancing mental wellness. Psilocybin interacts with serotonin 2A receptors and is useful in treating depression and addiction.
Conversely, MDMA promotes empathy and is effective in PTSD treatment. It demonstrates potential in improving emotional processing and
Therapeutic outcomes are still achievable, even though it’s classified as a controlled substance.
Is this treatment accessible to all Australians?
No, not everyone in Australia can access this treatment. Individuals are required to undergo an assessment to determine their eligibility for using this substance. The evaluation takes into account factors such as pre-existing heart conditions and a history of psychosis. Only patients who have not found relief from conventional treatments for ailments like depression, anxiety, or PTSD can avail of this treatment.
What are the implications of Canada exporting magic mushrooms?
Canada is poised to become a major player in the psychedelics market, mirroring its approach to cannabis. This could lead to an increase in companies producing top-quality products. As a result, Canada could lead the global hallucinogen market, strengthen its economy, and make these treatments more accessible to other countries. This could also prevent these countries from obtaining hallucinogens from illegal sources, thus ensuring safety.
Articles That Might Interest You:
